SCHEMBL20587605

SCHEMBL20587605

O=C(NN=Cc1cccc(Cl)c1O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.73
SMN1; SMN2 Q16637 4/20 0.73
LMNA P02545 3/20 0.73
KMT2A Q03164 3/20 0.73
HTT P42858 3/20 0.73
POLB P06746 3/20 0.73
PTBP1 P26599 2/20 0.73
TDP1 Q9NUW8 1/20 0.73
MAPT P10636 8/20 0.64
MEN1 O00255 2/20 0.64
HPGD P15428 3/20 0.59
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
HSP90AA1 P07900 1/20 0.56
GAA P10253 1/20 0.56
ALOX12 P18054 1/20 0.56
ADCYAP1R1 P41586 1/20 0.55
KDM1A O60341 1/20 0.54
GCGR P47871 1/20 0.52
CYP1A2 P05177 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20587603 1.00 KDM4E (0.73) KDM4ESMN1; SMN2LMNAKMT2AHTT
SCHEMBL22179481 1.00 KDM4E (0.73) KDM4ESMN1; SMN2LMNAKMT2AHTT
SCHEMBL683833 0.89 KDM4E (0.67) KDM4ESMN1; SMN2LMNAKMT2AHTT
SCHEMBL14898605 0.87 MAPT (0.65) KDM4ESMN1; SMN2LMNAKMT2AHTT
SCHEMBL22179516 0.86 MAPT (0.73) KDM4ESMN1; SMN2LMNAKMT2AHTT
SCHEMBL20587680 0.86 MAPT (0.73) KDM4ESMN1; SMN2LMNAKMT2AHTT
SCHEMBL20587677 0.86 MAPT (0.73) KDM4ESMN1; SMN2LMNAKMT2AHTT
SCHEMBL30067012 0.86 MAPT (0.73) KDM4ESMN1; SMN2LMNAKMT2AHTT
SCHEMBL6571628 0.85 KDM4E (0.74) KDM4ESMN1; SMN2LMNAKMT2AHTT
SCHEMBL6571625 0.85 KDM4E (0.74) KDM4ESMN1; SMN2LMNAKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12325678-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2025-06-10 US disclosed
US-20240124392-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-04-18 US disclosed
US-11858880-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-01-02 US disclosed
US-20220394973-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-12-15 US disclosed
US-11414378-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-08-16 US disclosed
US-20200207705-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-07-02 US disclosed
EP-3638649-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS The Research Foundation for The State University of New York (US) 2020-04-22 EP disclosed
WO-2018232298-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2018-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220394973-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS ERG28, UGCG, DPM1 KDM4E 1377/4885SMN1; SMN2 4407/4885LMNA 3665/4885
US-12325678-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids ERG28, UGCG, SMPD1 KDM4E 1113/4885SMN1; SMN2 4282/4885LMNA 3582/4885
US-20200207705-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS ERG28, UGCG, DPM1 KDM4E 1377/4885SMN1; SMN2 4407/4885LMNA 3665/4885
US-11858880-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids ERG28, UGCG, DPM1 KDM4E 1377/4885SMN1; SMN2 4407/4885LMNA 3665/4885
US-20240124392-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS ERG28, UGCG, DPM1 KDM4E 1377/4885SMN1; SMN2 4407/4885LMNA 3665/4885
US-11414378-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids ERG28, UGCG, LSS KDM4E 1060/4885SMN1; SMN2 4406/4885LMNA 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.